BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2014 2:06:00 PM | Browse: 587 | Download: 289
Publication Name World Journal of Clinical Oncology
Manuscript ID 8888
Country of Manuscript Source United States
Received
2014-01-11 12:52
Peer-Review Started
2014-01-11 13:36
To Make the First Decision
2014-02-13 16:02
Return for Revision
2014-02-20 20:44
Revised
2014-05-12 00:00
Second Decision
2014-05-29 15:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-29 15:55
Articles in Press
2014-05-29 16:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-24 14:17
Publish the Manuscript Online
2014-12-11 14:23
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript type Minireviews
Article Title Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer
Manuscript Source Unsolicited Manuscript
All Author List Muhammad Wasif Saif, Valerie Relias, Kostas Syrigos and Krishna S Gunturu
Funding Agency and Grant Number
Correspondence To Muhammad Wasif Saif Department of Medicine and Cancer Center Tufts Medical Center 800 Washington Street Box 245 Boston, MA 02111 USA Phone: +1-617.636.8077Fax: +1-617.636.7060 E-mail: wsaif@tuftsmedicalcenter.org
Keywords Ziv-aflibercept; Colon cancer; Metastatic; Bleeding; Hypertension
Core Tip Ziv is an anti-angiogenic agent which has shown survival benefit in colorectal cancer. Side effects of this drug include hypertension, bleeding, perforation and delayed wound healing among others. In this paper, we review the side effects of Ziv and discuss how to manage those toxicities.We here submit a comprehensive paper on on Ziv-aflibercept (also called as zaltrap). Ziv-aflibercept (Zaltrap, Ziv),a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)- binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human immunoglobulin IgG1. As Ziv is becoming widely used in general oncology practice, it is important to understand the toxicities and to develop practice guidelines for their management. We here provide a comprehensive review on the toxicities noted in trials using Ziv for the treatment of mCRC, and will provide recommendations for toxicity management. We believe that this paper is of utmost importance both to the patients as well as the treating physicians.
Publish Date 2014-12-11 14:23
Citation Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol 2014; 5(5): 1028-1035
Url http://www.wjgnet.com/2218-4333/full/v5/i5/1028.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i5.1028
Full Article (PDF) WJCO-5-1028.pdf
Full Article (Word) WJCO-5-1028.doc
Manuscript File 8888-Review.doc
Answering Reviewers 8888-Answering reviewers.pdf
Copyright License Agreement 8888-Copyright assignment.pdf
Peer-review Report 8888-Peer review(s).pdf
Scientific Misconduct Check 8888-CrossCheck.jpg
Scientific Editor Work List 8888-Scientific editor work list.pdf